E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary arterial hypertension (PAH) in children |
|
E.1.1.1 | Medical condition in easily understood language |
PAH is a deadly disease that causes narrowing of the pulmonary artery, which requires more effort from the heart to pump blood into the lungs, eventually leading to right heart failure. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064908 |
E.1.2 | Term | Associated with (APAH) |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064909 |
E.1.2 | Term | Idiopathic (IPAH) |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064910 |
E.1.2 | Term | Familial (FPAH) |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to demonstrate that 12 weeks of treatment with either dose (0.5 mg/kg b.i.d or 2 mg/kg b.i.d) of the bosentan dispersible tablet formulation improves PVRi in pediatric patients with PAH, aged from ≥ 1 year to < 17 years. |
|
E.2.2 | Secondary objectives of the trial |
The other objectives are to evaluate the following in this patient population:
- Other hemodynamic variables, WHO functional class, global clinical status, exercise capacity, time to clinical worsening.
- Tolerability and safety variables.
- Echocardiographic variables (imaging and Doppler evaluation).
- The steady-state PK of the bosentan dispersible tablet formulation at doses of 0.5 mg/kg b.i.d. and 2 mg/kg b.i.d.
- The PK-efficacy relationship on PVRi and other selected efficacy endpoints. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent by the parents or legal representatives prior to any study mandated procedure.
2. Male or female ≥ 1 year and < 17 years of age (maximum age
at randomization is 16 years and 9 months).
3. WHO functional class I–IV.
4. PAH diagnosed with Right Heart Catheterization (RHC).
5. PAH etiologies:
Idiopathic or heritable PAH,
or
Associated PAH persisting/recurrent for at least 6 months
after complete repair of a congenital heart defect,
or
CHD (PAH associated with systemic-to-pulmonary shunts
including Eisenmenger syndrome).
6. PVR > 3 Wood units for idiopathic, heritable PAH or PAH
persisting/recurrent after complete repaired of congenital
heart defect.
or
PVR > 8 Wood units for PAH associated with systemic-to-pulmonary open shunts with a ratio Qp/Qs < 2.
7. Body weight ≥ 8 kg and ≤ 95 kg.
8. Patients naïve to PAH-specific treatment
or
Patients already treated with PAH-specific medication at a stable dose since at least 3 months:
Prostanoids, PDE-5 inhibitors
No combination of PAH-specific therapy is allowed.
9. Patients naïve to PAH related, non-specific medication
or
Patients already treated with PAH related, non-specific medication, such as
Calcium channel blockers (stable dose since at least 3 months)
Anticoagulants
Diuretics
Digoxin
10. Females of childbearing potential must have a negative
pre-treatment pregnancy test and must use reliable methods of
contraception during the whole treatment period and for 1 month after study drug discontinuation. |
|
E.4 | Principal exclusion criteria |
1. Non-stable disease status, e.g., history of recurrent (near-)
syncope or signs and symptoms of non-compensated right heart failure.
2. Patients with bronchopulmonary dysplasia, congenital
diaphragmatic hernia or other chronic lung diseases.
3. Need or plan to wean patient from any PAH-specific therapies
during the study.
4. Systolic blood pressure < 80% of the lower limit of normal
range.
5. Aspartate aminotransferase (AST) and/or alanine
aminotransferase (ALT) values > 1.5 times the upper limit of
normal range.
6. Moderate or severe hepatic impairment (i.e., Child-Pugh Class
B or C).
7. Hemoglobin and/or hematocrit levels < 75% of the lower limit
of normal range.
8. Known intolerance or hypersensitivity to bosentan or any of
the excipients of the bosentan dispersible tablet.
9. Treatment with bosentan or any other endothelin receptor
antagonists within 4 months prior to randomization (including any ERA investigational drug).
10. Treatment with another investigational drug within 1 month
prior to randomization or planned treatment.
11. Pregnancy or breastfeeding.
12. Any condition that prevents compliance with the protocol or
adherence to therapy.
13. Administration of prohibited medication within 2 weeks or
5 times the half-life, prior to randomization, whichever is the
longest. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy endpoint = PVRi at Week 12 expressed as percent change from the baseline value.
‘baseline’ is defined as the last assessment performed prior to first study drug intake. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary efficacy endpoints = Change from baseline to Week 12 in RHC variables. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Prospective, group sequential |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Bulgaria |
Chile |
China |
Colombia |
Croatia |
France |
Guatemala |
India |
Malaysia |
Mexico |
Netherlands |
Peru |
Philippines |
Portugal |
Russian Federation |
Serbia |
Singapore |
South Africa |
Taiwan |
Ukraine |
United States |
Vietnam |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of Study is defined as the date on which the last randomized
patient, not prematurely withdrawn, completes the 12-week treatment and the 7-day AE follow-up period. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |